Total views : 353

Treatment of Myocardial Infarction by Stem Cell Based Therapy


  • Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram, Bangalore - 560 035, Karnataka, India


Purpose: Recently myocardial infarction is one of the leading causes of death worldwide. Myocardial infarction leads to the serious consequences which cause increase in mortality and morbidity. In myocardial infarction there is permanent loss of cardiomyocytes which results an irreversible loss of cardiac function. Cardiac repair requires the replacement, restoration and regeneration of heart function. Conventional therapies such as revascularization, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) prevent the additional damage to heart muscle and also reduce the risk of future heart attack. However, there is need to develop a new therapy to improve the infracted area after the myocardial infarction and also to lower the mortality rate.

Approaches: The data were collected from various sources like journal articles, internet, textbooks, related materials in library and databases such as Pubmed, Science Direct, Springer, Google Scholar and so on.

Findings: Stem cell-based therapy is found to be a much more promising therapy when compared to other available therapies. Stem cells therapy shows significantly improved heart function after myocardial infarction, therefore decline into heart failure.

Conclusion: Recently the interest is stem cell based therapies which provide the potential benefit and have ability to improve the cardiac function. In this review, we highlight the benefits of stem cells in cardiac repair.


Stem Cells, Totipotent, Pluripotent, Multipotent, Myocardial Infarction.

Full Text:

 |  (PDF views: 126)


  • Veronique L. R. Epidemiology of myocardial infarction. Medical Clinical of North America. 2007; 91(4):537 - 539.
  • The PREMISE program,2015. Prevention of Recurrence of Myocardial Infarction and Stroke Study. World Health Organization. Country project.
  • Upaganlawar A. Isoproterenol induced myocardial infarction. Protective Role of Natural Product. Journal of Pharmacology and Toxicology. 2011; 6(1):1-17.
  • Ashton Faulkner. Stem Cell Therapy: A New Approach for Treatment of Myocardial Infarction. Stem Cell Research and Therapy. 2001; S1-004:4172-7633.
  • Sheing-Tsung Kuo. Stem Cell Therapy for Acute Myocardial Infarction and Heart Failure- Past, Present and Future. Taiwan Society of Internal Medicine. 2009; 20:1-18.
  • Gupta BD. An introduction to stem cells and debate surrounding them. Journal Indian Academy of Forensic Medicine. 2009; 31(3):267.
  • ISSCR. International Society for Stem Cell Research. 2016.
  • Anand Krishna K. Myocardial Infarction and stem cells. Journal of Pharmacy and BioAllied Science. 2011; 3(2):182-188.
  • Acosta SA. Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction. Journal of Stem cell Research and Therapy. 2013 ; 4: 005.
  • Risheen R. Stem Cell Therapy in Acute Myocardial Infarction. Journal of Clinical and Experimental Cardiology. 2012; S11-004:2155-9880.
  • Frat C. Resident cardiac stem cells. Current Pharmaceutical Design. 2011; 17(30):3252-3257.
  • Bradfute SB. Cardiac progenitor cells from adult myocardium: homing differentiation and fusion after infraction. Proceedings of the National Academy of Sciences of the United States. 2003; 100:12313-12318.
  • Buckingham M.. Skeletal muscle stem cells. Current opinion in genetic and development. 2008; 18(4):330336.
  • Shah V.K. Stem Cell Therapy in Acute Myocardial Infarction: A plot of Gold or Pandora's Box. Stem Cell International. 2011; 20:20-24.
  • Wam M. In vivo self renewal of c-kit+ Sca-1+ Lin (low/-) hemopoietic stem cells. Journal of Immunology. 1996; 156(9):3207-3214.
  • Spangrude GJ. Purification and characteri-zation of mouse hematopoietic stem cells. Science. 1999; 241(4861):58-62.
  • Pittenger MF. Multilineage potential of adult human mesenchymal stem cel ls. Science. 1999; 284(5411):143-147.
  • M. ichew M. “Expression of VEGFR-2 and AC133 by circulating human CD34 (+) Cells identifies a population of function endothelial precursors”. Blood. 2000; 95(3):952-958.
  • Calvin CS. Current Stem Cell Delivery Method for Myocardial Repair. Biomedical Research International. 2013 ; 4:15.
  • Howard T. Walpole. Option for Stem Cell Delivery in Cardiology. Cardiac Catheteri-zation Laboratory. 2014; 2(1):e707.
  • Mummery CL. Challenges in using stem cell for cardiac repair. Science Translation Medicine. 2010;2:17.
  • Halkos ME. Intravenous infusion of mesenchymal stem cell enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Research in Cardiology. 2008; 103(6):525-536.
  • Dib N. Recommendations for successful training on method of delivery of biologist for cardiac regeneration: a report of the International Society for Cardiovascular Translation Research. Journal of the American College of Cardiology. 2010; 3(3):265-275.
  • Pilio G. Direct minimally invasive intramyo-cardial injection of bone marrow derived AC133+ stem cell in patient with refractory ischemia: preliminary result. Thoracic and Cardiovascular Surgeon. 2008; 56(2):7176.
  • Grossman PM. Incomplete retention after direct myocardial injec t ion. Catheter i zat ion and Cardiovascular Intervention. 2002; 55(3):392-397.
  • Mozid AM. Stem cell therapy for heart diseases. British Medical Bulletin. 2011; 98(1):143-159.
  • Sherman W. Catheter based delivery of cells to the heart. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S57-S64.
  • Thompson CA. Percutaneous transvenous cellular cardiomyoplasty: a novel nonsurgical approach for myocardial cell transplantation. Journal of the American College of Cardiology. 2003; 41(11):1964-1971.
  • Siminiak T. Post infarction heart failure: surgical and trans-coronary-venous transplan-tation of autologous myoblast. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S46-S51.
  • Saccheetti A. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pig and chronic experimental myocardial ischemia. Journal of the American College of Cardiology. 2001; 37(6):1726-1732.
  • Perin EC. Assessing myocardial viability and infract transmurality with left ventricular electromechanical mapping in patient with stable coronary artery disease: validation by delayed- enhancement magnetic resonance imaging. Circulation. 2002; 106(8):957-961.
  • Widimsky P. Intracoronary Transplantation of bone marrow stem cells: background, technique and limitation. European Heart Journal Supplement. 2006; 8:H16-H22.
  • Copland IB. Mesenchymal stromal cells for cardiovascular disease. Journal of Cardio-vascular Disease Research. 2011; 2(1); 3-13.
  • Suzuki K. Development of a novel method for cell transplantation through the coronary artery. Circulation. 2000; 102(19):III359-III364.
  • Yokoyama SI. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardial for the treatment of ischemic heart disease. Journal of Molecular and Cellular Cardiology. 2006; 40(1):24-34.
  • Vicario J. One year follow-up of transcoronary sinus administration of autologous bone marrow in patient with chronic ref ractory angina. Cardiovascular Revascularization Medicine. 2005; 6(3):99-107.
  • Sui R. The current status of engineering myocardial tissue. Stem Cell Review and Report. 2011; 7(1):172180.
  • Li Z. High- efficiency matrix modulus- induced cardiac differentiation of human mesenchymal stem cell inside a thermo sensitive hydrogel. Acta Biomaterialia. 2012; 8(10): 3586-3595.
  • Miyahara Y. Monolayered mesenchymal stem cell repair scarred myocardium after myocardial infarction. Nature Medicine. 2006; 12(4):459-465.
  • Hou D. Radio labeled cell distribution after intramyocardial, intracoronary and interstitial retrograde coronary venous delivery: implication for current clinical trials. Circulation. 2005; 112(9):I150-I156.
  • Andrew J. Stem Cell Therapy for Cardiac Repair. Circulation. 2006; 114:339-352.
  • Orlic D. Bone marrow cells regenerate infracted myocardium. Nature. 2001; 401:701-705.
  • Olivares EL. Bone marrow stromal cells improve cardiac performance in healed infracted rat hearts. American Journal of Physiology. 2004; 287:H464-470.
  • Schuster MD. Myocardial neovascularization by bone marrow angioblast results in cardiomyocyte regeneration. American Journal of Physiology. 2004; 287:H525-H532.
  • Tuch BE. Stem cells- a clinical update. Australian Family Physician. 2006; 35(6):719-721.
  • Mitsui K. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113(5):631-642.
  • He JQ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circulation Research. 2003; 93(1):3239.
  • Vanderlaan RD. Electrophysiological profiling of cardiomyocytes in embryonic bodies derived from embryonic stem cells. Circulation Research. 2003; 93(1):1-3.
  • Vawda R. Stem cells therapies for perinatal brain injuries. Seminars in Fetal and Neonatal Medicine.2001; 12(4):259-272.
  • Liu S. Mammary stem cells, self renewal pathways and carcinogenesis. Breast Cancer Research. 2005; 7(3):86-95.
  • Rolletschek A. Embryonic stem cell-derived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicology Letter. 2004; 149(1-3): 369-391.
  • Korbling M. Adult stem cells tissue repair- a new therapeutic concept. New England Journal of Medicine. 2003; 349(6):570-582.
  • Alonso L. Stem cells in the skin: waste not, Wnt not. Genes development. 2003; 17(10):1189-1200.